A human tumor-immune organoid model of glioblastoma
University of California, Los Angeles · UCLA Health
Abstract
A major obstacle to identifying effective therapies for the aggressive brain tumor glioblastoma is the lack of human-specific, immunocompetent models that reflect the human tumor microenvironment. To address this, we developed the immune-human organoid tumor transplantation (iHOTT) model, an autologous co-culture platform that integrates patient-derived tumor cells and matched peripheral blood mononuclear cells within human cortical organoids to enable the study of patient-specific immune responses and tumor-immune interactions. This platform preserves tumor and immune populations, immune signaling, and cell-cell interactions observed in patient tumors. Treatment of iHOTT with pembrolizumab, a checkpoint…
Citation impact
- FWCI
- 123.65
- Percentile
- 100%
- References
- 62
Authors
18Topics & keywords
- Organoid
- Glioblastoma
- Immune system
- Immunotherapy
- Peripheral blood mononuclear cell
- Brain tumor
- Transplantation
- Tumor cells
- Good health and well-being
Funding
- ACAmerican Cancer Society
- MEMcKnight Endowment Fund for Neuroscience
- PCPew Charitable Trusts
- APAlfred P. Sloan Foundation
- AAAlexander and Margaret Stewart Trust
- VFV Foundation for Cancer Research
- MFMcKnight Foundation
- SFSontag Foundation
- CICalifornia Institute of Technology
- RHRose Hills Foundation
- SASwim Across America
- UKUncle Kory Foundation
- NINational Institutes of HealthAwards: T32GM152342, P50CA211015
- NCNational Cancer InstituteAward: P50CA211015
- JCJonsson Comprehensive Cancer CenterAward: T32GM152342
- EAEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles
- DGDavid Geffen School of Medicine, University of California, Los Angeles